OS THERAPIES INC (OSTX) Stock News

Let's take a look at the stocks that are in motion in today's session.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Unusual volume stocks in Friday's session

Discover the stocks with unexpected trading volume in today's session on the US markets.

What's going on in today's session

Which stocks are experiencing notable movement on Friday?

Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

OS Therapies Announces Closing of $6 Million Private Placement

OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online

OS Therapies Announces Pricing of $6 Million Private Placement

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

OS Therapies to Present at The Spartan Capital Investor Conference

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

OS Therapies to Present at the LD Micro Main Event XVII

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (OSTX, ATNM, CRBP, PBYI)

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024

OS Therapies just reported results for the second quarter of 2024.

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

OS Therapies Clarifies CUSIP of Common Stock

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

OS Therapies Reports Second Quarter 2024 Financial Results

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board

OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”

Preview: Os Therapies Incorporated Set To IPO Tomorrow

OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer